Bromocriptine for cocaine dependence. A controlled clinical trial

American Journal on Addictions

Volumn 6, Issue 1, 1997, Pages 54-64

  Handelsman, Leonard ^a,b   Rosenblum, Andrew ^a   Palij, Michael ^a   Magura, Stephen ^a   Foote, Jeffery ^a   Lovejoy, Meg ^a   Stimmel, Barry ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; BROMOCRIPTINE MESILATE; COCAINE; METHADONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DEPENDENCE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

EID: 0031039048     PISSN: 10550496     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1521-0391.1997.tb00392.x     Document Type: Article

References (31)

1. Substance Abuse and Mental Health Services Administration: Preliminary Estimates from 1992 National Household Survey on Drug Abuse. Washington, DC, DHHS, 1993
2. Corty E, Ball J: Admissions to methadone maintenance, comparisons between programs, and implications for treatment. J Subst Abuse Treat 1987; 4:181-187
3. Magura S, Siddiqi Q, Freeman RC, et al: Cocaine use and help-seeking among methadone patients. Journal of Drug Issues 1991; 21: 629-645
4. Kosten TR: Neurobiology of abused drugs: opioids and stimulants. J Nerv Ment Dis 1990; 178:217-227
5. Witkin JM: Pharmacotherapy of cocaine abuse: preclinical development. Neurosci Biobehav Rev 1994; 18:121-142
6. Dackis CA, Gold MS: New concepts in cocaine addiction: the dopamine depletion hypothesis. Neurosci Biobehav Rev 1985; 9:469-477
7. Volkow ND, Hitzemann R, Wang GJ, et al: Long-term frontal brain metabolic changes in cocaine abusers. Synapse 1992; 11: 184-190
8. Cedarbaum JM, Schliefer LS: Drugs for Parkinson's disease, spasticity, and acute muscle spasm, in The Pharmacological Basis of Therapeutics, 8th Edition. Edited by Gilman AG, Rail TW, Nies AS, et al. New York, Pergamon, 1990, pp 463-484
9. Ho KY, Thorner MO: Therapeutic applications of bromocriptine in endocrine and neurological diseases. Drugs 1988; 36:67-82
10. Hubner CB, Koob GF: Bromocriptine produces decreases in cocaine self-administration in the rat. Neuropsychopharmacology 1990; 3:101-108
11. Kleven MS, Woolverton WL: Effects of bromocriptine and desipramine on behavior maintained by cocaine or food presentation in rhesus monkeys. Psychopharmacology 1988; 95:433-446
12. Wise RA, Murray A, Bozarth MA: Bromocriptine self-administration and bromocriptine-reinstatement of cocaine-trained and heroin-trained lever pressing in rats. Psychopharmacology 1990; 100:355-360
13. Dackis CA, Gold MS: Bromocriptine as treatment for cocaine abuse. Lancet 1985; 1151-1152
14. Kosten TR, Schumann B, Wright D: Bromocriptine treatment of cocaine abuse in patients maintained on methadone. Am J Psychiatry 1988; 145:381-382
15. Teller DW, Devenyi P: Bromocriptine in cocaine withdrawal - does it work? Int J Addict 1988; 23:1197-1205
16. Giannini AJ, Folts DJ, Feather JN, et al: Bromocriptine and amantadine in cocaine detoxification. Psychiatry Res 1989; 29:11-16
17. Magura S, Rosenblum A, Lovejoy M, et al: Neurobehavioral treatment for cocaine-using methadone patients: a preliminary report. J Addict Dis 1994; 13:143-160
18. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition, Revised. Washington, DC, American Psychiatric Association Press, 1987
19. Tennant FS Jr, Sagherian AA: Double-blind comparison of amantadine and bromocriptine for ambulatory withdrawal from cocaine dependence. Arch Intern Med 1987; 147:109-112
20. Dubbert PM, King A, Rapp SR, et al: Riboflavin as a tracer of medication compliance. J Behav Med 1985; 8:287-299
21. Babiker IE, Cooke PR, Gillett MG: How useful is riboflavin as a tracer of medication compliance? J Behav Med 1989; 12:25-38
22. Spitzer RL, Williams JEW, Gibbon M, et al: The Structured Clinical Interview for DSM-III-R (SCID), I: history, rationale, and description. Arch Gen Psychiatry 1992; 49:624-629
23. McNair DM, Lorr M, Droppleman LF: Profile of Mood States. San Diego, CA, Educational and Industrial Testing Service, 1971
24. Watson D, Clark LA, Tellegen A: Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 1988; 54:1063-1070
25. Preston KL, Sullivan JT, Strain EC, et al: Effects of cocaine alone and in combination with bromocriptine in human cocaine abusers. J Pharm Exp Ther 1992; 262:279-291
26. Eller K, Schaefer MR, Salstrom D, et al: Double-blind comparison of bromocriptine and placebo in cocaine withdrawal. Am J Drug Alcohol Abuse 1995; 21:65-79
27. Weddington WW Jr, Brown BS, Haertzen CA, et al: Comparison of amantadine and desipramine combined with psychotherapy for treatment of cocaine dependence. Am J Drug Alcohol Abuse 1991; 17:137-152
28. Kosten TR, Morgan CM, Falcione J, et al: Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine and desipramine. Arch Gen Psychiatry 1992; 49:894-898
29. Handelsman L, Limpitlaw L, Williams D, et al: Amantadine does not reduce cocaine use or craving in cocaine-dependent methadone maintenance patients. Drug Alcohol Depend 1995; 39:173-180
30. Hill JL, Wilkins JN, Gorelick DA: Double-blind outpatient trial of bromocriptine for treatment of cocaine abuse. Presented at the Annual Meeting of the College for Problems of Drug Dependency, Scottsdale, AZ, 1995
31. Krantzler HR, Bauer LO: Bromocriptine and cocaine cue reactivity in cocaine-dependent patients. Br J Addict 1992; 84:1537-154.